From the laboratory to the marketplace, Gary Veron advises pharmaceutical and biotechnology companies on the wide range of U.S. Food and Drug Administration (FDA) issues that arise during drug development and commercialization. In particular, Gary focuses on Hatch-Waxman Act and life cycle management issues.

As a registered patent attorney, Gary has vast experience handling issues that occur at the intersection of FDA and intellectual property laws. He draws on his unique background to counsel clients regarding comprehensive development strategies, including market exclusivity periods, Orange Book issues, and therapeutic equivalence determinations. Gary's practice includes the novel issues raised by biosimilar and 505(b)(2) applications.

Gary also has experience negotiating technology transfer and license agreements and managing patent prosecution matters. Before joining Hogan Lovells, Gary practiced food and drug law and patent law at another international law firm and was a Technology Development Specialist at the National Institutes of Health (NIH), where he served as the intellectual property manager for four NIH institutes.

Gary is a "Recommended Lawyer" in Legal 500 USA, and is listed in The Best Lawyers in America (FDA Law).